Floatz logo

FMISO

Brain Cancer

University of UtahSmall moleculePhase 1Dormant
CC
40/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Brain Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
University of California, Davis
Phase 2BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sorafenib
Virginia Commonwealth University
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
DIANHYDROGALACTITOL
Kintara Therapeutics, Inc.
Phase 2BB

View all 50 →

Same molecule, other indications

FMISO is also rated in:

triple-negative breast carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
giant cell glioblastomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →